LETTER TO THE EDITOR

Evaluation of SOX4 levels in multiple myeloma patients

Authors

Elisabetta Lombardi,[1] Kinga Eva Kowal,[1] Gonzalo Almanza,[2] Francesco Agostini,[1] Francesco Da Ros,[1] Marco Valvasori,[1] Carla Vicinanza,[1] Daniel Alzetta,[3] Barbara Montante,[3] Miriam Marangon,[1] Silvia Crestani,[3] Giuseppe Lamon,[3] Maurizio Rupolo,[3] Mario Mazzucato,[1] Cristina Durante,[1] Maurizio Zanetti[2] and Mariagrazia Michieli[3]

[1]Stem Cell Unit, Department of Research and Advanced Cancer Diagnostic, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy; [2]The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California San Diego, La Jolla, CA, USA and [3]Oncohematology and Cell Therapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy

Correspondence:
E. LOMBARDI - elombardi@cro.it

https://doi.org/10.3324/haematol.2024.286794

Received: November 19, 2024.
Accepted: April 29, 2025.
Early view: May 8, 2025.

Supp. Figure 1



A) **A representative cartoon to describe the link between multiple myeloma, inflammation and SOX4/CD56 axis**

B) **CD138+ cell isolation work flow**. Schematic rappresentation to samples processation: Buffy coat was obtained from bone marrow ACD collected blood and CD138+ cells were obtained by immunosoring using BD-MACS system

Supp. Table 1

Population parameters			
Average Age (years)	65		
Males (n/%)	42/62.7		
Females (n/%)	25/37.3		
Sample distribution	**n/%**	**Group characterization**	**Therapy line**
MGUS/SMM	9/10.9		
New Diagnosis MM (ND-MM)	31/37.3	I-RSS 1 n= 7 I-RSS 2 n= 15 I-RSS 3 n= 9	
Treated MM	43/51.8	Progression n=19 Follow-up n=8 Response n=16	1 Therapy line n= 23 2 Therapy lines n= 13 >3 Therapy lines n= 7

Mean age, gender distribution of the 67 patients, and the distribution of 83 biological samples obtained from MGUS/SMM (Monoclonal Gammopathy of Undefined Significance/ Smoldering multiple myeloma), New diagnosis MM (ND-MM) sample distribution was characterized on I-RSS code and Treated MM (T-MM) one on therapy line and response . Patients signed informed consent upon enrolment. Inclusion criteria were the following: age ≥ 18 years; candidate patients for diagnosis or staging of Multiple Myeloma by bone marrow biopsy; ability to express adequate consent to participate in the study. Exclusion criteria were the following: patient refusal to sign informed consent; inadequate or insufficient bone marrow aspirate material for analysis. All enrolled participants finished the study, i.e., there was no attrition